BriaCell Provides Clinical Update on Its Lead Vaccine Candidate, BriaVax
BriaCell Therapeutics Corp. ("BriaCell" or the "Company"), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today released a clinical update on its ongoing Phase I/IIa study of its lead vaccine candidate, BriaVax™, in advanced breast cancer patients.
View full press release